Search results

The study aims to add to the body of knowledge of open source tangible product management (also called open design). The objective is also to develop a guideline for efficient open source tangible product development and adoption.

The exploratory research design using secondary data (like newspapers, magazines, research articles, bogs, papers, etc.) is used to analyze open source tangible product design challenges and enablers. The success stories of Open Source Software projects (OSS) were studied for identification of critical success factors and further their relevancy was tested in the two popular cases of open source drug discovery (malaria and tuberculosis)

Open innovation has become a part of competitive strategy of current businesses. It requires an efficient intellectual property protection regime for its implementation. However, in a market dominated by proprietary benefits, the open source technology development can serve as remedy for innovation needs of neglected sectors. The OSS literature revealed managing two classes of factors, namely technology sponsor level factors and environmental factors for efficiency and effectiveness. The case study analysis in the context of applicability of these OSS critical factors showed their limitations in open source tangible products, and highlighted understanding additional challenges and remedies.

Open source innovation is a collaborative effort involving inputs from various/diverse players, hence monitoring the effort and motivation level of the contributors is a cumbersome task. Only the information that is available online and in print media is taken as research inputs in this work. Also the data taken were from two case studies; a lot more case studies in the open design domain can progress the theory. The implications of this study are far-reaching in the areas where profit motivated proprietary efforts lack in addressing societal need. It provides guidelines for addressing those unmet needs by developing products in a collaborative way without intellectual property hurdles.

The essence of open design is becoming more vital, and there is a pressing need to build theory to support it, which still is elusive and dispersed. The study fills the gap using secondary data and case study approach.

Through the example of a “regulatory ranking” – an index produced with the aim to regulate the pharmaceutical market by pushing companies in the direction of providing greater access to medicine in developing countries – this chapter focuses on indexing and ranking as infrastructural processes which inscribe global problem spaces as unfolding actionable territories for market intervention. It foregrounds the “Indexal thinking” which structures and informs regulatory rankings – their aspiration to align the interests of different stakeholders and to entice competition among the ranked companies. The authors detail the infrastructural work through which such ambitions are enacted, detailing processes of infrastructural layering/collage and patchwork through which analysts naturalize/denaturalize various contested categories in the ranking’s territory. They reflect on the consequences of such attempts at reconfiguring global topologies for the problems these governance initiatives seek to address.

The World Health Organization estimated that in 1999 roughly one-third of the world's population lacked access to essential medicines that would have saved or improved their lives. Our analysis focuses on how pharmaceutical product patents restrict access to essential medicines in developing countries. It is well established that pharmaceutical product patents provide little incentive for pharmaceutical companies to develop new medicines designed to treat diseases prevalent in developing countries or to market in developing countries those patented medicines developed to treat diseases prevalent in developed countries. Economists have developed theoretical models showing that these incentives could be changed if (1) developing countries provided intellectual property protection for new pharmaceutical innovations and (2) an international regulatory framework were established to facilitate pharmaceutical companies setting lower prices in developing countries and higher prices in developed countries for patented medicines. We develop an index of property rights in pharmaceutical innovations covering 129 countries from 1960 to 2005. It shows that in 1960 only a handful of countries provided significant protection for pharmaceutical innovations, but by 2005 over 95 percent of countries in our sample provided significant statutory protections. However, an international framework to allow pharmaceutical companies to price discriminate has not been put in place. We conclude that international price discrimination mechanisms, compulsory patent licenses, and regional patent buyouts are not viable mechanisms for providing access to essential medicines to patients in developing countries. Global patent buyouts are more likely to achieve this goal, as they are not founded on an impractical separation of pharmaceutical markets in developing and developed countries and they provide critical incentives to develop new essential medicines.

The purpose of this paper is to provide a review of an Australian health promoting schools (HPS) project to identify key features of the concept of resilience and how it can be used in a school setting to develop and strengthen protective factors in young people, as a mechanism for improving social functioning and reducing involvement in risk behaviours.

Methods used in the “Resilient Children and Communities” project are described. Then a revue of the academic literature published on theoretical and empirical findings from the “Resilient Children and Communities” project is presented.

The papers reviewed indicate there is a developing body of evidence to show that the “HPS” is an efficient and effective approach to building resilience amongst school children. Underpinned by Bronfenbrenner's broad ecological framework, benefits have been derived not only for students, but for the whole school community. Such benefits include not only building self-esteem and self-efficacy, peer relationships and relationships between students, teachers and parents, but also school connectedness and feelings of belonging.

The findings from this project provide a strong evidence base identifying the central role of “resilience” in the school culture. This role is cross-cultural and transnational and evidence that resilience can strengthen protective factors has clear implications for the African context, where communicable diseases and neglected tropical diseases pose intractable problems, typically in resource restricted environments.

These findings provide insight into the central role of the school setting in building resilience. Resilience, in turn, can help students survive and thrive under challenging and adverse conditions.

This paper aims to examine the role of information and communication technology (ICT) in the knowledge creation practices adopted by a health care organization. The organization is delivering care to patients of a genetic disorder, called the sickle cell, in tribal communities. The paper identifies how ICT intermediates knowledge creation practices across the organizational boundaries wherein tribal patients, front-line counselors and expert physicians interact, which then produces context-specific, evidence-based medicine (EBM).

The knowledge-in-practice approach is adopted to conduct an ethnographic study of sickle cell care practices in a non-profit health care organization in Western India. The analysis focuses on ICT-mediated interactional practices among the physicians, front-line counselors, tribal patients and their families, for more than a year-long observation. These are supplemented with informal and formal interviews, archival records and vignettes based on several episodes to explicate the key knowledge creation practices.

Technology-mediated informative interactions at organizational boundaries can bridge socio-linguistic and interpretive barriers between actors, while also providing a generative structure that leads to the creation of longitudinal clinical evidence about a rare genetic disorder. Three specific ICT-entwined knowledge creation practices emerge, namely, knowing the community, increasing interactional engagement and constructing gradients of socio-clinical history. These practices generate organization-wide knowledge about the social and clinical dimensions of the genetic disorder. The findings are presented through vignettes and a novel conceptual framework.

This study identifies various useful knowledge creation practices in health care delivery for resource-constrained emerging economy contexts. Further, the study suggests that the involvement of local front-line actors and ICT can become important resources in the delivery of health care in these settings.

A novel framework is developed which demonstrates knowledge creation at organizational boundaries wherein the actors use ICT-based practices for effective delivery of health care. The proposed framework may be used by health care organizations in similar contexts providing care to marginalized communities.

Health in low-income countries has become associated with the provision of minimum guaranteed public health services though Essential Health Packages (EHPs). How far do EHPs deliver the human right to health for all? This study addresses this question through qualitative research into access to health care for vulnerable communities, using Malawi as a case study. This study shows that there are significant accountability gaps and perceptions of weak service provision in Malawi’s EHP in relation to some particularly marginalised (and stigmatised) groups that limit the right to health and the promise of “health for all”.

This study extends the body of qualitative work on EHPs in general and on Malawi in particular by exploring the perceptions of key stakeholders in relation to inclusivity and the delivery of health policies to particularly vulnerable groups. To do so, this study adopted an approach based on interpretive epistemologies (Scott, 2014). This study conducted largely unstructured interviews with a range of health stakeholders, speaking to stakeholders individually, rather than through focus groups due to the potentially sensitive nature of the topic.

The findings of this study are as follows: limited inclusion of civil society actors and local communities; local communities and local policymakers feel frustration with the gap between the promises of consultation in the EHP and the reality, and the difficulties of not having effective channels of communication; and exclusionary health practices for particularly vulnerable groups.

There are limitations based on the qualitative methodology, and in terms of the particularly vulnerable groups – the authors studied two such groups (people with disabilities and those who identify as LBTQ) but a wider survey of vulnerable groups is needed to extend and confirm the findings.

Greater attention to the health rights of vulnerable groups would improve access and services, even in the context of resource restrictions. This study suggests that a deeper engagement with human rights-based approaches would pay dividends in terms of increasing access to health in Malawi, even within the constraints of the EHP process. Furthermore, without this, there is the risk that discrimination and exclusion will become more embedded in health policies, rather than progressively minimised.

Without addressing these issues, there is the risk that discrimination and exclusion will become more embedded in health policies, rather than progressively minimised.

This paper makes an important contribution to the growing literatures on EHP in sub-Saharan Africa and Malawi in particular and to the importance of listening to stakeholder perceptions. It provides original data on stakeholder perspectives of the challenges associated with universalising health care in resource-constrained countries. To the best of the authors’ knowledge, it is one of the first papers to focus on the rights of disabled and LBTQ people in relation to EHPs.

The initial policy of the countries that developed vaccines has been to lock the vaccine by patent. This has been due to the fact that domestic demand for vaccine was mounting. Since only a few countries could invest in it, manufacturing and export remained at the behest of those few resulting in deep inequity in the global rollout. Pandemics are global health crises. Hence, calls for the patent waiver for the COVID-19 vaccine are growing to access the vaccine. The vaccine and its production, marketing and distribution have been politicized driven by the hegemonic aspiration. Both manufacturing and import-dependent countries are racing to win the diplomatic battle: the former has to win to gain hegemony and the latter to get the vaccine. Hence, the vaccine distribution has been marked with deep discrimination, and as a result, the migrant community is less likely to get their vaccine on time. This article engages in the decades-long debate over intellectual property rights and patenting life-saving vaccines. We argue that exemption of COVID-19 vaccines from intellectual property rights would improve global access and equity.

The purpose of this paper is to explore the extent of visibility of researchers in African countries, in the Open Access (OA) arena and aims to identify main causes of reduced uptake in OA in Africa.

Extent of visibility is explored by quantitative analysis of institutional repository and OA journals data sets followed by qualitative analysis of OA foundation documents and literature on OA in Africa published mainly between 2003 and 2013.

Visibility in institutional repositories or OA journals for African researchers remains low. Causes include insufficient educational support for librarians and administrators in required new roles; inability of national, organisational and technological infrastructures to support OA; impracticality of western-based and costly publishing models; and disincentives relating to intellectual property and researcher perceptions. Complex language and literacy issues also inhibit engagement. Recommendations include strong OA advocacy, development of support initiatives, integration of international knowledge for local conditions and vice versa, sensitive preservation of indigenous knowledge and development of mechanisms of funding and research assessment mechanisms, which are economically and technically viable.

Earlier attempts were made to raise awareness about the lack of uptake of OA in Africa. This paper shows that the situation has hardly changed and now requires urgent attention. Otherwise OA will not “become the default method for distributing new peer-reviewed research in every field and country” by 2022 (BOAI, 2012).

There is sufficient evidence to prove that the improved health status of a nation’s citizens results in economic growth and development via improved functionality and productivity of labor. It is also commonly accepted that healthcare expenditure significantly influences health status through, for instance, improving life expectancy at birth and reducing morbidity, death, and infant mortality rates. Within healthcare, medicines account for a considerable share of health-related expenditure in both developed and developing countries. Therefore, it seems reasonable to assume that improved access to medicines is likely to contribute not only to the well-being of families and individuals but also to the economic growth and development in all societies. It has been widely advocated that pharmaceutical multinational enterprises (MNEs) can play an important role to address this problem, as they develop and supply a significant proportion of the drugs imported by low- and middle-income countries. This chapter is dedicated to a systematic review of literature in order to identify the strategies implemented by pharmaceutical MNEs to improve access to medicines in the low- and middle-income countries. A total of 76 research articles have been identified, and we have found that the main strategies of pharmaceutical MNEs are related to improving health outcomes through R&D, establishing partnerships for product development, pricing strategies to improve access to medicines, technology transfer, licensing agreements, and nonmarket efforts to improve access to medicines, among other strategies to overcome barriers imposed by intellectual property rights. We have also found that pharmaceutical MNEs’ strategies take place within a complex system and often involve interactions with a wide range of actors, such as international organizations, governments, private not-for-profit sector, universities and research institutes, and generic manufacturers. However, there is still a need for major progress in the field of access to medicines, and pharmaceutical MNEs should be more active in this field in order to avoid potential negative consequences, such as loss of legitimacy and compulsory licensing of their patented medicines.